The European Commission has officially approved Luxturna (voretigene neparvovec), Novartis AG’s one-time gene therapy for inherited retinal dystrophy caused by RPE65 gene mutations.
This is the company’s first move into gene therapy and the approval is something of a landmark for Novartis. What happens now will have ramifications for how it develops this part of its business
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?